Table 2 Intracellular MTX-PG and eryfolate levels (n = 43)
RBC MTX-PG, in nmol/L | median | IQR | Delta RBC MTX-PG, in nmol/L | median | IQR |
MTX-PG2, median (IQR) | |||||
 Start protocol Ma | 1.4 | (1.2–2.4) |  |  |  |
 After Course 1 | 8.0 | (4.9–15.5) |  |  |  |
 After Course 2 | 12.6 | (6.7–23.8) | Course 2 – Course 1 | + 1.9 | (−0.8–7.9) |
 After Course 3 | 11.0 | (6.1–20.6) | Course 3 – Course 2 | −1.7 | (−8.7–1.5) |
 After Course 4 | 10.8 | (6.2–25.3) | Course 4 – Course 3 | + 0.2 | (−5.4–8.3) |
MTX-PG3, median (IQR) | |||||
 Start protocol Ma | 2.5 | (1.3–3.9) |  |  |  |
 After Course 1 | 14.3 | (9.4–19.6) |  |  |  |
 After Course 2 | 26.2 | (20.5–34.7) | Course 2 – Course 1 | + 11.3 | (8.4–17.4) |
 After Course 3 | 31.1 | (20.6–39.9) | Course 3 – Course 2 | + 4.2 | (0.1–7.6) |
 After Course 4 | 33.0 | (27.1–43.5) | Course 4 – Course 3 | + 3.1 | (− 5.5–10.9) |
MTX-PG4, median (IQR) | |||||
 Start protocol Ma | 2.2 | (1.3–2.5) |  |  |  |
 After Course 1 | 20.2 | (11.2–28.3) |  |  |  |
 After Course 2 | 35.8 | (24.5–56.3) | Course 2 – Course 1 | + 16.6 | (9.0–27.5) |
 After Course 3 | 46.5 | 31.2–59.1) | Course 3 – Course 2 | + 7.6 | (3.8–13.2) |
 After Course 4 | 48.7 | (34.0–71.4) | Course 4 – Course 3 | + 10.0 | (−4.4–16.2) |
MTX-PG5, median (IQR) | |||||
 Start protocol Ma | 1.6 | (1.1–2.0) |  |  |  |
 After Course 1 | 18.2 | (8.3–22.8) |  |  |  |
 After Course 2 | 29.9 | (22.0–45.2) | Course 2 – Course 1 | + 12.8 | (7.5–23.1) |
 After Course 3 | 36.5 | (20.6–49.3) | Course 3 – Course 2 | + 6.6 | (1.7–11.0) |
 After Course 4 | 42.9 | (23.6–56.5) | Course 4 – Course 3 | + 6.2 | (−8.6–13.0) |
Sum MTX-PG2–5, median (IQR) | |||||
 Start protocol Ma | 7.5 | (4.2–9.2) |  |  |  |
 After Course 1 | 60.7 | (41.0–92.0) |  |  |  |
 After Course 2 | 113.0 | (76.8–165.2) | Course 2 – Course 1 | + 43.0 | (27.9–80.1) |
 After Course 3 | 131.6 | (88.9–170.7) | Course 3 – Course 2 | + 19.4 | (−0.9–33.0) |
 After Course 4 | 141.3 | (100.2–190.2) | Course 4 – Course 3 | + 15.2 | (−18.7–44.7) |
RBC Folate, in nmol/L | Â | Â | Delta RBC Folate, in nmol/L | Â | Â |
5-methylTHF, median (IQR) | |||||
 Start protocol Ma | 185.7 | (97.8–215.7) |  |  |  |
 After Course 1 | 150.3 | (56.6–300.6) |  |  |  |
 After Course 2 | 218.3 | (91.1–386.4) | Course 2 – Course 1 | + 82.2 | (−0.6–146.3) |
 After Course 3 | 227.8 | (151.2–384.3) | Course 3 – Course 2 | + 23.2 | (−48.8–67.8) |
 After Course 4 | 228.9 | (134.9–356.0) | Course 4 – Course 3 | + 33.6 | (−71.5–107.0) |
Non-methylTHF, median (IQR) | |||||
 Start protocol Ma | 42.6 | (27.9–67.7) |  |  |  |
 After Course 1 | 61.9 | (39.8–132.7) |  |  |  |
 After Course 2 | 88.1 | (49.3–169.7) | Course 2 – Course 1 | + 1.8 | (−24.4–82.7) |
 After Course 3 | 106.3 | (63.2–208.8) | Course 3 – Course 2 | + 14.2 | (−90.9–56.7) |
 After Course 4 | 94.8 | (59.0–163.9) | Course 4 – Course 3 | −6.9 | (−80.2–54.4) |
Folic acid, median (IQR) | |||||
 Start protocol Ma | 11.8 | (8.0–13.7) |  |  |  |
 After Course 1 | 11.5 | (7.9–21.1) |  |  |  |
 After Course 2 | 17.3 | (10.1–22.3) | Course 2 – Course 1 | −0.9 | (−5.3–4.7) |
 After Course 3 | 13.3 | (7.7–20.8) | Course 3 – Course 2 | −4.3 | (−11.5–1.4) |
 After Course 4 | 13.0 | (9.0–24.8) | Course 4 – Course 3 | + 2.0 | (−8.1–8.5) |
Sum folate, median (IQR) | |||||
 Start protocol Ma | 255.2 | (151.7–290.9) |  |  |  |
 After Course 1 | 290.1 | (152.7–453.8) |  |  |  |
 After Course 2 | 401.6 | (163.3–594.2) | Course 2 – Course 1 | + 75.9 | (−51.0–194.9) |
 After Course 3 | 411.5 | (240.3–665.6) | Course 3 – Course 2 | + 39.4 | (−169.1–128.1) |
 After Course 4 | 361.5 | (217.5–511.0) | Course 4 – Course 3 | + 20.6 | (− 162.4–199.6) |
Ratio RBC Folate / MTX-PG2–5 |  |  | Delta Ratio RBC Folate / MTX-PG2–5 | ||
 After Course 1 | 4.7 | (2.7–6.9) |  |  |  |
 After Course 2 | 3.3 | (2.2–5.2) | Course 2 – Course 1 | −2.6 | (−9.7–0.1) |
 After Course 3 | 3.4 | (1.8–5.5) | Course 3 – Course 2 | −0.7 | (−2.4–0.9) |
 After Course 4 | 2.7 | (1.7–4.5) | Course 4 – Course 3 | − 0.6 | (− 2.1–1.3) |